Literature DB >> 3164727

Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle.

P M Stewart1, J E Corrie, C H Shackleton, C R Edwards.   

Abstract

The first adult case of 11 beta-hydroxysteroid dehydrogenase (11 beta-OHSD) deficiency is described. The impaired conversion of cortisol to cortisone (indicated by urinary cortisol and cortisone metabolites and failure to metabolize 11 alpha-[3H]cortisol to [3H]H2O), was associated with hypertension, hypokalemia, and suppression of the renin-angiotensin-aldosterone system. When established on a fixed Na+/K+ intake, dexamethasone, given orally, produced a natriuresis and potassium retention. Plasma renin activity became detectable. When hydrocortisone (10 mg daily s.c. for 4 d) was added, there was marked Na+ retention, a kaliuresis (urinary Na+/K+ falling from 1.2 to 0.15), with suppression of plasma renin activity and an increase in blood pressure. These changes were also seen with the subject on no treatment. Conversion of cortisone to cortisol was not affected. These results suggest that cortisol acts as a potent mineralocorticoid in 11 beta-OHSD deficiency. The major site for the oxidation of cortisol to cortisone is the kidney. In this patient congenital deficiency of 11 beta-OHSD results in high intrarenal cortisol levels which then act on renal type I mineralocorticoid receptors. This condition can be treated with dexamethasone, which suppresses cortisol secretion and binds to the type II glucocorticoid receptor. We suggest that 11 beta-OHSD exerts a critical paracrine role in determining the specificity of the type I receptor. In the normal state cortisol is converted by 11 beta-OHSD to cortisone which thus allows aldosterone to bind preferentially to the type I receptors in the kidney and gut. In this patient deficiency of 11 beta-OHSD results in high intrarenal cortisol concentrations that then bind to the type I receptor.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3164727      PMCID: PMC303514          DOI: 10.1172/JCI113592

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension.

Authors:  M I New; L S Levine; E G Biglieri; J Pareira; S Ulick
Journal:  J Clin Endocrinol Metab       Date:  1977-05       Impact factor: 5.958

2.  The effect of dexamethasone on the activity of 11beta-hydroxysteroid dehydrogenase in the foetal rabbit lung during the final stage of gestation.

Authors:  M A Lugg; T E Nicholas
Journal:  J Pharm Pharmacol       Date:  1978-09       Impact factor: 3.765

3.  Hemodynamic characteristics of primary aldosteronism.

Authors:  R C Tarazi; M M Ibrahim; E L Bravo; H P Dustan
Journal:  N Engl J Med       Date:  1973-12-20       Impact factor: 91.245

4.  Plasma cortisone concentration as measured by radioimmunoassay.

Authors:  L S Srivastava; E E Werk; K Thrasher; L J Sholiton; R Kozera; W Nolten; H C Knowles
Journal:  J Clin Endocrinol Metab       Date:  1973-05       Impact factor: 5.958

5.  Dihydrocortisol: a potential mineralocorticoid.

Authors:  D Marver; I S Edelman
Journal:  J Steroid Biochem       Date:  1978-01       Impact factor: 4.292

6.  Renal capture and oxidation of cortisol in man.

Authors:  L Hellman; F Nakada; B Zumoff; D Fukushima; H L Bradlow; T F Gallagher
Journal:  J Clin Endocrinol Metab       Date:  1971-07       Impact factor: 5.958

7.  Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age.

Authors:  P M Stewart; A M Wallace; R Valentino; D Burt; C H Shackleton; C R Edwards
Journal:  Lancet       Date:  1987-10-10       Impact factor: 79.321

8.  Subtraction potential difference: In-vivo assay for mineralocorticoid activity.

Authors:  F Skrabal; J Auböck; C R Edwards; H Braunsteiner
Journal:  Lancet       Date:  1978-02-11       Impact factor: 79.321

9.  The metabolism of cortisol by human extra-hepatic tissues.

Authors:  J S Jenkins
Journal:  J Endocrinol       Date:  1966-01       Impact factor: 4.286

10.  An abnormality in steroid reductive metabolism in a hypertensive syndrome.

Authors:  S Ulick; L C Ramirez; M I New
Journal:  J Clin Endocrinol Metab       Date:  1977-04       Impact factor: 5.958

View more
  61 in total

Review 1.  Investigation of hypertension and the recognition of monogenic hypertension.

Authors:  D V Milford
Journal:  Arch Dis Child       Date:  1999-11       Impact factor: 3.791

Review 2.  Apparent mineralocorticoid excess syndromes.

Authors:  M Shimojo; P M Stewart
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

Review 3.  Primary aldosteronism.

Authors:  R D Gordon
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

4.  Evidence for cortisol as the mineralocorticoid in the syndrome of apparent mineralocorticoid excess.

Authors:  R Tedde; A Pala; A Melis; S Ulick
Journal:  J Endocrinol Invest       Date:  1992-06       Impact factor: 4.256

5.  Persistent hypokalemia after successful adrenalectomy in a patient with Cushing's syndrome due to ectopic ACTH secretion: possible role of 11beta-hydroxysteroid dehydrogenase inhibition.

Authors:  E Arteaga; C Fardella; C Campusano; I Cárdenas; P Martinez
Journal:  J Endocrinol Invest       Date:  1999-12       Impact factor: 4.256

6.  Mineralocorticoids in the management of primary adrenocortical insufficiency.

Authors:  M Jadoul; A Ferrant; J F De Plaen; J Crabbé
Journal:  J Endocrinol Invest       Date:  1991-02       Impact factor: 4.256

7.  Corticosteroid-regulated genes in rat kidney: mining time series array data.

Authors:  Richard R Almon; William Lai; Debra C DuBois; William J Jusko
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-06-28       Impact factor: 4.310

8.  Hsd11b2 haploinsufficiency in mice causes salt sensitivity of blood pressure.

Authors:  Matthew A Bailey; Eilidh Craigie; Dawn E W Livingstone; Yuri V Kotelevtsev; Emad A S Al-Dujaili; Christopher J Kenyon; John J Mullins
Journal:  Hypertension       Date:  2011-01-31       Impact factor: 10.190

9.  Epigenetic regulation of 11 beta-hydroxysteroid dehydrogenase type 2 expression.

Authors:  Rasoul Alikhani-Koopaei; Fatemeh Fouladkou; Felix J Frey; Brigitte M Frey
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

10.  Serum Cortisol-to-Cortisone Ratio and Blood Pressure in Severe Obesity before and after Weight Loss.

Authors:  James B Byrd; Amy E Rothberg; Robert Chomic; Charles F Burant; Robert D Brook; Richard J Auchus
Journal:  Cardiorenal Med       Date:  2015-09-09       Impact factor: 2.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.